JULIE BOOM to Adolescent
This is a "connection" page, showing publications JULIE BOOM has written about Adolescent.
Connection Strength
0.755
-
Factors Associated With COVID-19 Non-vaccination in Adolescents Hospitalized Without COVID-19. J Pediatric Infect Dis Soc. 2023 Feb 09; 12(1):29-35.
Score: 0.053
-
Development of a Spanish version of the parent attitudes about childhood vaccines survey. Hum Vaccin Immunother. 2019; 15(5):1106-1110.
Score: 0.040
-
Arboviral Surveillance among Pediatric Patients with Acute Febrile Illness in Houston, Texas. Am J Trop Med Hyg. 2018 08; 99(2):413-416.
Score: 0.038
-
Prevalence of Vaccine Hesitancy Among Expectant Mothers in Houston, Texas. Acad Pediatr. 2018 03; 18(2):154-160.
Score: 0.036
-
Parental report of vaccine receipt in children with autism spectrum disorder: Do rates differ by pattern of ASD onset? Vaccine. 2016 Mar 08; 34(11):1335-42.
Score: 0.033
-
Investigation of obstacles to accessing information regarding private medical insurance coverage and physician reimbursement for adolescent vaccination. J Adolesc Health. 2009 Mar; 44(3):298-301.
Score: 0.020
-
Pediatric Vaccine Effectiveness Against Influenza Hospitalization and Outpatient Visits: 2021-2024. Pediatrics. 2026 May 01; 157(5).
Score: 0.017
-
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026. MMWR Morb Mortal Wkly Rep. 2026 Mar 12; 75(9):116-123.
Score: 0.016
-
Influenza Vaccine Effectiveness Among Children With and Without Underlying Conditions. Pediatrics. 2026 Feb 01; 157(2).
Score: 0.016
-
Influenza Antiviral Use in Hospitalized Children Before and During the COVID-19 Pandemic. Pediatrics. 2026 Feb 01; 157(2).
Score: 0.016
-
Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study. Clin Infect Dis. 2025 Oct 06; 81(3):623-633.
Score: 0.016
-
Changes in Antiviral Prescribing for Children With Influenza in US Emergency Departments. JAMA Netw Open. 2025 Oct 01; 8(10):e2538729.
Score: 0.016
-
Clinical Testing for COVID-19, Influenza, and RSV in Hospitalized Youths, 2016-2024. JAMA Netw Open. 2025 Sep 02; 8(9):e2531499.
Score: 0.016
-
Human Metapneumovirus and Respiratory Syncytial Virus in Children: A Comparative Analysis. Pediatrics. 2025 Sep 01; 156(3).
Score: 0.016
-
Acute Gastroenteritis Among Household Contacts of Children with Severe Norovirus Gastroenteritis, United States, 2011-2016. J Pediatric Infect Dis Soc. 2025 Jun 16; 14(6).
Score: 0.016
-
Adenovirus Species in U.S. Children With Acute Respiratory Illness, 2016-2019. J Pediatric Infect Dis Soc. 2025 Jun 16; 14(6).
Score: 0.016
-
Prevalence of human adenovirus in children with acute gastroenteritis in the New Vaccine Surveillance Network (NVSN) from 2016 to 2019. J Clin Virol. 2025 Aug; 179:105822.
Score: 0.016
-
Antiviral Prescription in Children With Influenza in US Emergency Departments: New Vaccine Surveillance Network (NVSN), 2016-2020. Influenza Other Respir Viruses. 2025 Jun; 19(6):e70124.
Score: 0.015
-
Epidemiology and genotypic diversity of rhinovirus in school-age children with acute respiratory illnesses seeking medical care. J Clin Virol. 2025 Aug; 179:105806.
Score: 0.015
-
Enterovirus D68-Associated Respiratory Illness in Children. JAMA Netw Open. 2025 05 01; 8(5):e259131.
Score: 0.015
-
The Epidemiology and Burden of Human Parainfluenza Virus Hospitalizations in US Children. J Pediatric Infect Dis Soc. 2025 Apr 08; 14(4).
Score: 0.015
-
Pediatric Clinical Influenza Disease by Type and Subtype 2015-2020: A Multicenter, Prospective Study. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).
Score: 0.015
-
Estimated Vaccine Effectiveness for Pediatric Patients With Severe Influenza, 2015-2020. JAMA Netw Open. 2024 12 02; 7(12):e2452512.
Score: 0.015
-
Underutilization of Influenza Antiviral Treatment Among Children and Adolescents at Higher Risk for Influenza-Associated Complications - United States, 2023-2024. MMWR Morb Mortal Wkly Rep. 2024 Nov 14; 73(45):1022-1029.
Score: 0.015
-
Prevalence of SARS-CoV-2 in Children Identified by Preprocedural Testing at 5 US Children's Hospital Systems. Pediatr Infect Dis J. 2025 Jan 01; 44(1):47-53.
Score: 0.015
-
Influenza C virus in U.S. children with acute respiratory infection 2016-2019. J Clin Virol. 2024 10; 174:105720.
Score: 0.015
-
Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023. MMWR Morb Mortal Wkly Rep. 2024 Apr 18; 73(15):330-338.
Score: 0.014
-
Accuracy of Influenza ICD-10 Diagnosis Codes in Identifying Influenza Illness in Children. JAMA Netw Open. 2024 04 01; 7(4):e248255.
Score: 0.014
-
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):168-174.
Score: 0.014
-
Circulation of Rhinoviruses and/or Enteroviruses in Pediatric Patients With Acute Respiratory Illness Before and During the COVID-19 Pandemic in the US. JAMA Netw Open. 2023 02 01; 6(2):e2254909.
Score: 0.013
-
Clinical Presentation and Severity of Adenovirus Detection Alone vs Adenovirus Co-detection With Other Respiratory Viruses in US Children With Acute Respiratory Illness from 2016 to 2018. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):430-439.
Score: 0.013
-
Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses - New Vaccine Surveillance Network, United States, 2016-2021. MMWR Morb Mortal Wkly Rep. 2022 Oct 07; 71(40):1253-1259.
Score: 0.013
-
Vaccine Effectiveness Against Influenza Hospitalization and Emergency Department Visits in 2 A(H3N2) Dominant Influenza Seasons Among Children <18 Years Old-New Vaccine Surveillance Network 2016-2017 and 2017-2018. J Infect Dis. 2022 08 12; 226(1):91-96.
Score: 0.013
-
BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med. 2022 05 19; 386(20):1899-1909.
Score: 0.012
-
Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 14; 71(2):52-58.
Score: 0.012
-
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. N Engl J Med. 2022 02 24; 386(8):713-723.
Score: 0.012
-
Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 - Six Hospitals, United States, July-August 2021. MMWR Morb Mortal Wkly Rep. 2021 12 31; 70(5152):1766-1772.
Score: 0.012
-
Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-November 2018-2020. MMWR Morb Mortal Wkly Rep. 2021 Nov 26; 70(47):1623-1628.
Score: 0.012
-
Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 22; 70(42):1483-1488.
Score: 0.012
-
Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study. Pediatrics. 2021 08; 148(2).
Score: 0.012
-
Incomplete Records as a Leading Cause of Missed Opportunity for Human Papillomavirus Vaccine Initiation in a Safety Net Health System. Acad Pediatr. 2021 Sep-Oct; 21(7):1118-1125.
Score: 0.011
-
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children: Multicenter Surveillance, United States, January-March 2020. J Pediatric Infect Dis Soc. 2020 Nov 10; 9(5):609-612.
Score: 0.011
-
Vaccine Effectiveness Against Pediatric Influenza Hospitalizations and Emergency Visits. Pediatrics. 2020 11; 146(5).
Score: 0.011
-
Enterovirus D68-Associated Acute Respiratory Illness - New Vaccine Surveillance Network, United States, July-October, 2017 and 2018. MMWR Morb Mortal Wkly Rep. 2019 Mar 29; 68(12):277-280.
Score: 0.010